- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01192997
Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)
A Phase 2/3, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY (Menveo) or GSK Meningococcal ACWY Conjugate Vaccine in Adolescents Primed With Meningitec, Menjugate or Neisvac-C in Preschool Vaccination
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Between 550 and 650 subjects enrolled in a previous Meningococcal C vaccine study will be invited to join this new study looking at the boosting effects of two quadrivalent meningococcal ACWY vaccines. If they choose to participate, they will be randomised to receive one of the ACWY vaccines. Within each vaccine group, there will be further division into short (6 months) or longer (9 months) follow-up.
Each participant will be given one dose of an allocated vaccine. Blood samples will be taken three times from each participant - the first sample will be pre-vaccination; the second sample will be taken one month after vaccination; and the third and final sample at either six or nine months after vaccination (depending on the group they are randomised to).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW9 5EQ
- Health Protection Agency, Immunisation Department, Colindale
-
-
Gloucestershire
-
Gloucester, Gloucestershire, United Kingdom
- Multiple General Practice surgeries
-
-
Hertfordshire
-
Hertford, Hertfordshire, United Kingdom
- Multiple General Practice surgeries
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previously enrolled on the Preschool Men C study conducted by NVEC in 1999/2000
- Participant's parent or legally authorized representative is willing and able to give written informed consent for participation after the nature of the study has been explained.
- No contraindications to vaccination as specified in the "Green Book"- Immunisation against Infectious Disease, HMSO.
- Participant who gives assent for participation in the study.
- Vaccinated with Meningitec (MCC CRM) or Menjugate (MCC CRM) or NeisVac-C (MCC TT) between 3.5-6 years of age.
- Known to be free of medical problems as determined by a medical history and clinical assessment.
- Parent or legally authorised representative is willing to allow his or her child's GP to be notified of participation in the study and contacted if required for confirmation of vaccination history.
Exclusion Criteria:
- History of invasive meningococcal disease.
- Have a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitis disease in the previous 60 days.
- Any vaccination against MenC disease since MCC vaccine given between 3.5 to 6 years.
- Participant is pregnant.
- Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
- Major congenital defects or serious chronic disease including progressive neurological disease or seizure disorder.
- Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.
- Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study.
- In the event that administration of another licensed vaccine is needed during the study, this vaccine should not be administered within 30 days of any study injection according to investigator's judgment (exception: licensed flu-vaccine should not be administered within 14 days of study vaccines).
- Have received any blood or blood products within the past 12 weeks.
- Have any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
Temporary Exclusion Criteria
• Receipt of systemic antibiotics (either oral or parenteral) will delay enrolment until at least 7 days after cessation of antibiotics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Menveo-Meningitec
Subjects who were primed with Meningitec who will receive Novartis Menveo
|
Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
|
Active Comparator: MenACWY-TT-Meningitec
Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
|
Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
|
Active Comparator: Menveo-Menjugate
Subjects who were primed with Menjugate who will receive Novartis Menveo
|
Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
|
Active Comparator: MenACWY-TT-Menjugate
Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
|
Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
|
Active Comparator: Menveo-NeisVac-C
Subjects who were primed with NeisVac-C who will receive Novartis Menveo
|
Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
|
Active Comparator: MenACWY-TT-NeisVac-C
Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
|
Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to meningococcal components of the vaccines by serum bactericidal antibody
Time Frame: December 2013
|
Percentage of participants with serogroup-specific rabbit Serum Bactericidal Antibody (rSBA) titres ≥ 8 at one month post vaccination, for each of the serogroups A, C, W135 and Y. (This titre of rSBA is a documented correlate of protection for meningococcal conjugate vaccines)
|
December 2013
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Elizabeth Miller, MD, Public Health England
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Meningococcal Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
Other Study ID Numbers
- PRIME
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisSpain, Italy, United Kingdom, Czech Republic
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisKorea, Republic of
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisUnited States, Canada
-
Novartis VaccinesNovartisCompletedMeningococcal Disease | Meningococcal MeningitisUnited States
-
NovartisNovartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisAustralia, Canada
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
Clinical Trials on Menveo
-
Massachusetts General HospitalBill and Melinda Gates Foundation; Kenya Medical Research InstituteActive, not recruiting
-
GlaxoSmithKlineCompletedMeningococcal DiseaseKorea, Republic of
-
GlaxoSmithKlineCompletedMeningitis, MeningococcalSpain, Finland, Estonia, South Africa, Brazil, Mexico, Russian Federation, France, Turkey
-
Canadian Immunization Research NetworkUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
-
University of OxfordNovartis VaccinesCompleted
-
Leiden University Medical CenterCompletedMeningococcal DiseaseNetherlands
-
Novartis VaccinesCompletedMeningococcal InfectionsCanada, United States
-
University of OxfordCompletedMeningitis | Meningococcal Disease | SepticaemiaUnited Kingdom
-
GlaxoSmithKlineCompleted
-
University of OxfordCompleted